6 stories found
Israeli drugmaker Teva Pharmaceuticals has announced plans to purchase select assets from BioXcel Therapeutics in a deal valued at up to $125 million, expanding its portfolio in neuroscience and rare disease treatments.
A range of companies, including Allarity Therapeutics, Beam Global, and Boot Barn, have released their latest quarterly financial results. These reports detail GAAP EPS, revenue figures, and often include earnings call transcripts or highlights.
Struggling biotechnology company BioXcel Therapeutics has filed for Chapter 11 bankruptcy protection and formally entered into an asset sale agreement to transfer its remaining intellectual property and product portfolio to Israeli drugmaker Teva Pharmaceuticals.
H.C. Wainwright has revised its outlook for BioXcel Therapeutics, Inc. (BTAI) following concerns regarding the company's capital structure. The adjustment reflects the analyst firm's updated assessment of the company's financial health.
Teva has submitted a $57.5 million bid to acquire an agitation treatment asset from BioXcel Therapeutics, marking a strategic move in its specialty portfolio.
Legence announced its latest financial results, reporting a GAAP EPS of -$0.55, which missed analyst estimates by $0.59, but its revenue of $737.64 million surpassed expectations by $118.33 million.